In the last trading session, 80924.0 Atara Biotherapeutics Inc (NASDAQ:ATRA) shares changed hands as the company’s beta touched 0.53. With the company’s per share price at $13.33 changed hands at $1.13 or 9.26% during last session, the market valuation stood at $76.55M. ATRA’s last price was a discount, traded about -196.32% off its 52-week high of $39.50. The share price had its 52-week low at $6.50, which suggests the last value was 51.24% up since then. When we look at Atara Biotherapeutics Inc’s average trading volume, we note the 10-day average is 91400.0 shares, with the 3-month average coming to 103.03K.
Analysts gave the Atara Biotherapeutics Inc (ATRA) stock a consensus recommendation rating of Sell, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 1 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ATRA as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. Atara Biotherapeutics Inc’s EPS for the current quarter is expected to be -2.34.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Atara Biotherapeutics Inc (NASDAQ:ATRA) trade information
Instantly ATRA was in green as seen at the end of in last trading. With action 28.40%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 3.67%, with the 5-day performance at 28.40% in the green. However, in the 30-day time frame, Atara Biotherapeutics Inc (NASDAQ:ATRA) is 15.87% up. Looking at the short shares, we see there were 0.64 million shares sold at short interest cover period of 7.11 days.
The consensus price target for the stock as assigned by Wall Street analysts is 14, meaning bulls need an upside of 4.79% from its current market value. According to analyst projections, ATRA’s forecast low is 10 with 18 as the target high. To hit the forecast high, the stock’s price needs a -35.03% plunge from its current level, while the stock would need to tank 24.98% for it to hit the projected low.
Atara Biotherapeutics Inc (ATRA) estimates and forecasts
Data shows that the Atara Biotherapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 82.18% over the past 6 months, a 81.43% in annual growth rate that is considerably higher than the industry average of 16.70%. Year-over-year growth is forecast to reach 1,406.92% up from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 33.09M. 2 analysts are of the opinion that Atara Biotherapeutics Inc’s revenue for the current quarter will be 37.35M. The company’s revenue for the corresponding quarters a year ago was 4.25M and 27.36M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 678.34%. The estimates for the next quarter sales put growth at 36.53%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 13.12%. The 2024 estimates are for Atara Biotherapeutics Inc earnings to increase by 90.56%.
ATRA Dividends
Atara Biotherapeutics Inc is expected to release its next quarterly earnings report in January.
Atara Biotherapeutics Inc (NASDAQ:ATRA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 22.15% of Atara Biotherapeutics Inc shares while 50.82% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 65.29%. There are 50.82% institutions holding the Atara Biotherapeutics Inc stock share, with BOXER CAPITAL, LLC the top institutional holder. As of 2024-06-30, the company held 0.1181% of the shares, roughly 0.17 million ATRA shares worth $1.41 million.
LAKE STREET ADVISORS GROUP, LLC holds the second largest percentage of outstanding shares, with 0.0078% or 11000.0 shares worth $93500.0 as of 2024-06-30.
